Intervention: Rituximab combined with Daratumumab(Anti-CD38 Monoclonal Antibody)
Found 6 matching trials
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
PHASE1
This is a Phase I open-label, multicenter study designed to evaluate the sa...
Status
Terminated
Location
Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center